ABSTRACT
Background The exact mechanisms underlying paediatric abdominal pain (AP) remain unclear due to patient heterogeneity. This study aimed to identify AP phenotypes and develop predictive models to explore associated factors.
Methods In 13,790 children from a large birth cohort, data on paediatric and maternal demographics and comorbidities were extracted from general practitioner records. Machine learning (ML) clustering was used to identify distinct AP phenotypes, and an ML-based predictive model was developed using demographics and clinical features.
Results 1,274 children experienced AP (9.2 %) (average age: 8.4 ± 1.1 years, male/female: 615/659), who clustered into three distinct phenotypes: Phenotype 1 with an allergic predisposition (n = 137), Phenotype 2 with maternal comorbidities (n = 676), and Phenotype 3 with minimal other comorbidities (n = 340). As the number of allergic diseases or maternal comorbidities increased, so did the frequency of AP, with 17.6% of children with ≥ 3 allergic diseases and 25.6% of children with ≥ 3 maternal comorbidities. The predictive model demonstrated moderate performance in predicting paediatric AP (AUC 0.67), showing that a child’s ethnicity, paediatric allergic diseases, and maternal comorbidities were key predictive factors. When stratified by ML-predicted probability, observed AP rates were 18.9% in the <40% group, 44.8% in the 40–50% group, 60.6% in the 50–60% group, and 100.0% in the >60% group.
Conclusions Our findings reveal distinct phenotypes and associated factors of paediatric AP by an ML approach. These insights suggest potential targets for future research to clarify the underlying mechanisms of paediatric AP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by JA Niigata Kouseiren Grant (Niigata University School of Medicine) and JSPS Grants-in-Aid for Scientific Research (grant number: 22K16013).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used human data that are available with permission.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# H.Satti and Q.Aziz are joint senior authors.
Conflicts of interest: None declared.
Funding information: This study was supported by JA Niigata Kouseiren Grant (Niigata University School of Medicine) and JSPS Grants-in-Aid for Scientific Research (grant number: 22K16013).
We reanalyzed the data and updated the figures.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
